Trump ibogaine – The Trump administration is moving to fast-track FDA review of ibogaine, a Schedule I psychedelic sought by veterans’ groups for PTSD and traumatic brain injury treatment. The shift comes as the executive order boosts psychedelic research funding and expands “
In the Oval Office, the joke was the entry point. The urgency came from what the administration and veterans’ advocates say ibogaine can do for people living with PTSD and traumatic brain injuries—and from the stakes they put on every delay.
Ibogaine is a psychedelic drug classified as a Schedule I substance at the federal level, meaning it is illegal under federal law. Yet the Trump administration has turned it into a central agenda item, with a stated focus on potential treatments for opioid addiction and, more intensely, for PTSD.
Veterans and veterans’ groups have pushed for ibogaine for months. Their momentum accelerated when President Donald Trump signed an executive order last month aimed at fast-tracking Food and Drug Administration review of certain psychedelics. The order also includes language intended to expand access through an existing pathway created for experimental drugs.
The push has drawn attention beyond government circles. In a conversation about the drug policy shift. freelance journalist Mattha Busby described how podcaster Joe Rogan has been involved in the ibogaine conversation for years. Busby said Rogan discussed psychedelics on his podcast since it began. including bringing on people who have backed ibogaine and other psychedelic research. Busby described an “unlikely duo” from Rogan’s show—Aubrey Marcus and Rick Perry—along with a Kentucky lawyer and ibogaine advocate named Bryan Hubbard.
Busby said Rogan and the ibogaine advocates appeared to urge the administration to move quickly. He described an account that Rogan texted Donald Trump about making it happen. with Trump reportedly responding almost immediately: “Sounds good. Do you want FDA approval?” Busby also said Rogan attended the signing of the executive order at the White House.
The executive order names ibogaine as the focus drug. It also draws on the Right to Try Act that Trump signed in his first term. which is intended to allow end-of-life patients to try experimental drugs. In the order. that pathway is set to be extended to psychedelics. “so long as the DEA doesn’t try and obstruct that process. ” Busby said in the excerpt.
The order includes “five or six prongs,” with one major component earmarking $50 million for psychedelic research. Busby said most of that funding is expected to support state-led initiatives to investigate ibogaine and to allow a US-first human trial. He also described the order as intended to accelerate the route to potential approval by fast-tracking candidate applications: three candidates that had just submitted their data were fast-tracked so their applications would be considered more quickly.
Still, the administration’s push sits inside a warning label. Busby emphasized that the executive order should not be read as a blanket endorsement of use. “But we shouldn’t be under any illusions,” he said in the excerpt. “This is a seriously potent and dangerous psychedelic when used improperly.”
That caution has a factual basis in the risks cited by advocates and critics alike. Busby said there has been “a whole spate of deaths,” and he argued those deaths may be underreported because ibogaine disrupts the QT interval in the heart and can lead in some cases to fatal cardiac arrest.
The political shift is not happening in a vacuum. Busby described dissonance within the parties—particularly within the GOP, which has long been associated with the war on drugs. He said he sees the war on drugs “coming to an end little by little. ” even as rhetoric persists. and he called the moment a “significant threshold.”.
He also pointed to how previous changes in drug policy arrived through piecemeal moves rather than a single abrupt pivot. Busby referenced legislation Joe Biden introduced as a senator, aimed at crack cocaine punishments that he said were about 30 times more stringent than those for powder cocaine.
The immediate reason the order centers on veterans, Busby said, is that veterans’ accounts have been difficult to refute politically. He described the lobbying as rooted in traumatic effects that families and communities see every day. He cited a statistic that “22 veterans. on average. are committing suicide in the US every day.” In the Oval Office. Busby said Trump told the crowd: “Since 9/11. we’ve we’ve lost over 21 times more veteran lives to suicide than on the battlefield.”.
Busby also described a Stanford study from a couple of years ago that looked at 30 ex-special forces soldiers and found that a dose of ibogaine reduced their traumatic brain injury “significantly.”
Even with those claims—together with the administration’s funding and FDA acceleration—no one involved in the conversation suggests the path is simple. Busby said it’s “quite likely really, within this presidency,” that several psychedelic drugs could receive approval. Yet he framed the advance as a fast-moving effort that still depends on clinical evidence and on how safely the drugs can be used.
As the executive order moves from signing to implementation. the core tension remains plain in the facts themselves: ibogaine’s federal illegality as a Schedule I drug stands alongside a new federal push to speed review and broaden experimental access. propelled by veterans’ testimony and a looming deadline of human pain—and tempered by warnings that it can be deadly when misused.
Trump ibogaine psychedelics FDA PTSD veterans traumatic brain injury Right to Try Act DEA Schedule I opioid addiction Rick Perry Joe Rogan